Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

Author:

Dreno Brigitte1,Ascierto Paolo Antonio2,McArthur Grant A.3,Atkinson Victoria4,Liszkay Gabriella5,Di Giacomo Anna Maria6,Mandalà Mario7,Demidov Lev V.8,Stroyakovskiy Daniil9,Thomas Luc10,De la Cruz-Merino Luis11,Dutriaux Caroline12,Garbe Claus13,Rooney Isabelle Anne14,Hsu Jessie J.15,Park Erica16,Ribas Antoni17,Larkin James M. G.18

Affiliation:

1. Dermatology Departement, CHU Nantes, Nantes, France;

2. National Tumour Institute Fondazione G. Pascale, Naples, Italy;

3. Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia;

4. University of Queensland, Brisbane, Australia;

5. National Institute of Oncology, Budapest, Hungary;

6. Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy;

7. Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy;

8. N.N. Blokhin Russian Cancer Research Center, Moscow, Russia;

9. Moscow City Oncology Hospital #62, Moscow, Russian Federation;

10. Lyon University, Cancerology Institute of Lyon Civic Hospital, Cancer Research Centre of Lyon, Lyon, France, Pierre Benite, France;

11. Hospital Universitario Virgen Macarena, Sevilla, Spain;

12. Dermatology and Pediatric dermatology department, Bordeaux hospital, Bordeaux, France, Bordeaux, France;

13. Eberhard Karls University, Tübingen, Germany;

14. Genentech, Inc., San Francisco, CA;

15. Genentech, Inc., South San Francisco, CA;

16. Genentech, South San Francisco, CA;

17. University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA;

18. The Royal Marsden Hospital, London, United Kingdom;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3